© 2020 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.

Advertisement
map South America Brazil
Man With HIV Is in Long-Term Viral Remission After Intensified Treatment
IAS 2020
Click Here for the Latest From the 23rd International AIDS Conference
Click Here for the Current Issue of POZ
Truvada pills

UPDATED: COVID-19 Has Disrupted PrEP Use and STI Testing

However, PrEP still remains widely available, often provided via telemedicine.

10,000 Free In-Home HIV Tests Provided to Meet Growing Need

Because of COVID-19, HIV testing nationwide has plummeted as much as 70%.

Virtual HIV Jobs Fair at USCHA 2020

The U.S. Conference on HIV/AIDS aims to be a hub for HIV job openings, particularly jobs created to end the HIV epidemic.

UAlbany Launches an HIV Research Center Focused on Social Justice

New York collaborators will also address the related epidemics of hepatitis C, sexually transmitted infections and opioid use.

Dolutegravir Use at Conception Not Tied to Neural Tube Defects After All

A 2018 report had suggested that HIV-positive women’s use of the drug at conception increased the risk of the rare birth defects.

MUST read

Larry Kramer
Everything Larry Kramer
Novel coronavirus SARS-CoV-2
UPDATED: What People With HIV Need to Know About the New Coronavirus
The Truth About the 7,000
Mark S. King: I Wrote “The Truth About the 7,000.” Now What?
Listen Now: Signorile and King Discuss “The Truth About the 7,000”
#African American
#Latino
#Women

Injectable PrEP Is Even More Effective Than Daily Truvada

The placebo-controlled trial compared injections of cabotegravir given every eight weeks versus daily Truvada as PrEP.

CDC: Most Americans Don’t Know How They Got the New Coronavirus

Only 46% can trace the source of their infection—usually a family member or a coworker.

Switching HIV Meds to Biktarvy Is Safe, Effective Among Seniors

Pooled results from recent studies found a high rate of full viral suppression and no major safety concerns.

POZ Poll: Has COVID-19 caused you to miss doses of your HIV meds?

Global HIV Treatment Rates Rise, but Progress Is Uneven

Disruptions in access to antiretroviral treatment due to the COVID-19 pandemic could lead to a major setback in combating HIV.

Hot topics

Forums: Support and discussion
Blogs: The community speaks
POZ Stories: Get inspired
Magazine: Search the archives
HIV: The Basics
Recursos de VIH/SIDA en Español
AIDS Is Everyday
Ask POZ

Simplified HIV Treatment Linked to Greater Inflammation

Two-drug antiretroviral regimens suppress viral load, but three-drug combos may offer additional benefits.

10 Ways to Improve the International AIDS Conferences

Competing conference HIV2020 offers the recommendations to help #ReclaimTheResponse and engage those affected by HIV.
Judge John G. Roberts Jr.

How Recent SCOTUS Rulings Will Impact the HIV Community

The Supreme Court handed down two wins and a loss.

FDA Approves Rukobia for People With Multidrug-Resistant HIV

The novel attachment inhibitor led to viral suppression in 60% of people with extensive prior treatment.
Advertisement
Newsfeed
Treatment News
Features
Opinions